Fort Worth, Texas, April 28, 2026, 10:58 CDT
Shares of Omnicell Inc. surged Tuesday, as the medication-management tech firm topped analyst forecasts for both first-quarter earnings and sales, while also boosting its profit target for 2026. The upbeat results fueled momentum for Titan XT, Omnicell’s latest automated dispensing system targeting hospitals and health systems.
Timing is key here. Hospital procurement teams are up against leaner budgets, staff gaps, and rising expenses, leaving them to scrutinize automation investments carefully. Omnicell is betting those constraints will push hospitals toward its technology—systems that let nurses and pharmacists manage, secure, and dispense medications with fewer hands-on steps.
First-quarter revenue at the company climbed 15% to $310 million, driven by stronger sales of connected devices and growth across technical services, SaaS, and expert services. GAAP net income landed at $11 million, or 25 cents per diluted share, swinging from a loss of $7 million, or 15 cents per share, in the same period last year.
Adjusted earnings landed at 55 cents per share, handily beating the 33-cent consensus. Revenue reached $309.88 million, also surpassing the $304.01 million forecast, data from Investing.com shows. Shares jumped roughly 17.5% to $44.22 in late morning, after touching $48.48 earlier.
Omnicell bumped its full-year non-GAAP EPS outlook, now expecting $1.80 to $2.00, up from its earlier range of $1.65 to $1.85. Non-GAAP figures leave out certain expenses that show up in standard accounting. EBITDA—earnings before interest, taxes, depreciation and amortization—remains a go-to metric for investors comparing operating performance.
Randall Lipps, who heads Omnicell as chairman, president and CEO, described the quarter as a “strong start to 2026,” highlighting “sustained demand” for the company’s point-of-care systems—those cabinets and software installed at hospital bedsides and clinics. According to Lipps, customers are seeking out reliability, efficiency, and greater standardization in their medication workflows. Business Wire
Titan XT’s launch is still in its early innings. Management confirmed initial orders landed this quarter, with hardware deliveries not slated until the back half of 2026. As for OmniSphere, Omnicell aims to introduce its cloud platform—designed to connect devices, data, and workflows—on a phased timeline starting in the first half of 2027.
Omnicell now finds itself chasing after replacement and upgrade dollars in what it describes as an especially tough market. BD’s Pyxis medication dispensing systems are also in the mix, offering hospitals tools for inventory tracking, drug access, and systemwide standardization.
Nnamdi Njoku, executive vice president for innovation and products, told the earnings call that customers want “system-wide visibility” and more options for migration as they consider new medication management tools. According to him, feedback from Omnicell’s recent rounds of customer meetings has been upbeat, and the company is still working to grow its sales pipeline. The Motley Fool
Here’s the wrinkle: Omnicell flagged that health-system capital approvals often drag on—sometimes stretching out over several quarters, even years. The company expects most of its 2026 product bookings to land later in the year. Its 2026 guidance also factors in roughly $12 million in tariff-related costs, though management cautioned those tariffs could shift.
Omnicell wrapped up March holding $239 million in cash and cash equivalents, with $168 million in total debt. Its $350 million revolving credit facility remained untapped. Operating cash flow came in at $55 million, up from $26 million a year ago. That boost gives Omnicell more flexibility to back the Titan XT and OmniSphere shift, as investors keep an eye on the pace of new orders.
